0 false false false false false false false false false true false false false false false false No description of principal activity 2023-02-01 Sage Accounts Production Advanced 2021 - FRS102_2021 xbrli:pure xbrli:shares iso4217:GBP 08441767 2023-02-01 2024-01-31 08441767 2024-01-31 08441767 2023-01-31 08441767 bus:RegisteredOffice 2023-02-01 2024-01-31 08441767 bus:OrdinaryShareClass1 2023-02-01 2024-01-31 08441767 bus:LeadAgentIfApplicable 2023-02-01 2024-01-31 08441767 bus:Director1 2023-02-01 2024-01-31 08441767 bus:Director2 2023-02-01 2024-01-31 08441767 bus:CompanySecretary1 2023-02-01 2024-01-31 08441767 core:WithinOneYear 2024-01-31 08441767 core:WithinOneYear 2023-01-31 08441767 core:AfterOneYear 2024-01-31 08441767 core:AfterOneYear 2023-01-31 08441767 bus:OrdinaryShareClass1 2022-02-01 2023-01-31 08441767 core:ShareCapital 2024-01-31 08441767 core:ShareCapital 2023-01-31 08441767 core:RetainedEarningsAccumulatedLosses 2024-01-31 08441767 core:RetainedEarningsAccumulatedLosses 2023-01-31 08441767 core:CostValuation core:Non-currentFinancialInstruments 2024-01-31 08441767 core:Non-currentFinancialInstruments 2024-01-31 08441767 core:Non-currentFinancialInstruments 2023-01-31 08441767 bus:SmallEntities 2023-02-01 2024-01-31 08441767 bus:AuditExemptWithAccountantsReport 2023-02-01 2024-01-31 08441767 bus:AbridgedAccounts 2023-02-01 2024-01-31 08441767 bus:SmallCompaniesRegimeForAccounts 2023-02-01 2024-01-31 08441767 bus:PrivateLimitedCompanyLtd 2023-02-01 2024-01-31 08441767 bus:OrdinaryShareClass1 2024-01-31 08441767 bus:OrdinaryShareClass1 2023-01-31 08441767 1 2023-02-01 2024-01-31
COMPANY REGISTRATION NUMBER: 08441767
BASPHARM LIMITED
Filleted Unaudited Abridged Financial Statements
For the year ended
31 January 2024
BASPHARM LIMITED
Abridged Financial Statements
Year ended 31 January 2024
Contents
Page
Officers and professional advisers
1
Chartered certified accountants report to the board of directors on the preparation of the unaudited statutory abridged financial statements
2
Abridged statement of financial position
3
Notes to the abridged financial statements
5
BASPHARM LIMITED
Officers and Professional Advisers
The board of directors
Mr S. S. Basra
Mrs S. K. Basra
Company secretary
Mrs S. K. Basra
Registered office
111a George Lane
London
UK
E18 1AN
Accountants
OMG
Chartered Certified Accountants
111a, George Lane
London
E18 1AN
BASPHARM LIMITED
Chartered Certified Accountants Report to the Board of Directors on the Preparation of the Unaudited Statutory Abridged Financial Statements of BASPHARM LIMITED
Year ended 31 January 2024
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the abridged financial statements of BASPHARM LIMITED for the year ended 31 January 2024, which comprise the abridged statement of financial position and the related notes from the company's accounting records and from information and explanations you have given us. As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at www.accaglobal.com/en/member/professional-standards/rules-standards/acca-rulebook.html. This report is made solely to the Board of Directors of BASPHARM LIMITED, as a body, in accordance with the terms of our engagement letter dated 12 March 2013. Our work has been undertaken solely to prepare for your approval the abridged financial statements of BASPHARM LIMITED and state those matters that we have agreed to state to you, as a body, in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at www.accaglobal.com/content/dam/ACCA_Global/Technical/fact/technical-factsheet-163.pdf. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than BASPHARM LIMITED and its Board of Directors, as a body, for our work or for this report.
It is your duty to ensure that BASPHARM LIMITED has kept adequate accounting records and to prepare statutory abridged financial statements that give a true and fair view of the assets, liabilities, financial position and profit of BASPHARM LIMITED. You consider that BASPHARM LIMITED is exempt from the statutory audit requirement for the year. We have not been instructed to carry out an audit or a review of the abridged financial statements of BASPHARM LIMITED. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory abridged financial statements.
OMG Chartered Certified Accountants
111a, George Lane London E18 1AN
26 October 2024
BASPHARM LIMITED
Abridged Statement of Financial Position
31 January 2024
2024
2023
Note
£
£
£
Fixed assets
Investments
5
812,713
812,713
Current assets
Cash at bank and in hand
638
1,121
Creditors: amounts falling due within one year
483,747
385,005
---------
---------
Net current liabilities
483,109
383,884
---------
---------
Total assets less current liabilities
329,604
428,829
Creditors: amounts falling due after more than one year
237,701
317,643
---------
---------
Net assets
91,903
111,186
---------
---------
Capital and reserves
Called up share capital
6
1,000
1,000
Profit and loss account
90,903
110,186
--------
---------
Shareholders funds
91,903
111,186
--------
---------
These abridged financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the abridged statement of income and retained earnings has not been delivered.
For the year ending 31 January 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its abridged financial statements for the year in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of abridged financial statements .
All of the members have consented to the preparation of the abridged statement of income and retained earnings and the abridged statement of financial position for the year ending 31 January 2024 in accordance with Section 444(2A) of the Companies Act 2006.
BASPHARM LIMITED
Abridged Statement of Financial Position (continued)
31 January 2024
These abridged financial statements were approved by the board of directors and authorised for issue on 26 October 2024 , and are signed on behalf of the board by:
Mr S. S. Basra
Director
Company registration number: 08441767
BASPHARM LIMITED
Notes to the Abridged Financial Statements
Year ended 31 January 2024
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 111a George Lane, London, E18 1AN, UK.
2. Statement of compliance
These abridged financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The abridged financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The abridged financial statements are prepared in sterling, which is the functional currency of the entity.
Going concern
At the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.
Revenue recognition
The turnover shown in the profit or loss account represents dividend income receivable during the year from its subsidiary, Clinichem Ltd.
Investments
Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses.
Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.
Investments in associates
Investments in associates accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in associates accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably without undue cost or effort, the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the associate arising before or after the date of acquisition.
Investments in joint ventures
Investments in jointly controlled entities accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in jointly controlled entities accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably without undue cost or effort, the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the joint venture arising before or after the date of acquisition.
Impairment of fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.
4. Dividends
Dividends paid during the year (excluding those for which a liability existed at the end of the prior year):
2024
2023
£
£
Dividends on equity shares
132,000
132,000
---------
---------
5. Investments
£
Cost
At 1 February 2023 and 31 January 2024
812,713
---------
Impairment
At 1 February 2023 and 31 January 2024
---------
Carrying amount
At 31 January 2024
812,713
---------
At 31 January 2023
812,713
---------
6. Called up share capital
Issued, called up and fully paid
2024
2023
No.
£
No.
£
Ordinary shares of £ 1 each
1,000
1,000
1,000
1,000
-------
-------
-------
-------
7. Related party transactions
The company's turnover comprises entirely from dividends paid by its wholly owned subsidiary Clinichem Ltd. Baspharm Limited is the ultimate controlling party of Clinichem Ltd.
8. Controlling party
The company was under the control of Mr S S Basra , the managing director, thoughout the current and previous year.